Supporting better medication adherence in the community for people with dementia using Biodose Connect® and appropriate educatio
Completed
- Conditions
- Early Alzheimer’s DementiaMental and Behavioural Disorders
- Registration Number
- ISRCTN64300560
- Lead Sponsor
- Quantum Pharmaceutical
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
1. Male or female
2. Diagnosis of Alzheimer’s disease
3. Managed in community setting
4. On more than one oral medication
5. Willing and able to provide informed consent
Exclusion Criteria
1. Unable to provide fully informed consent
2. Admitted to hospital or care home/nursing home
3. Non-Alzheimer's dementia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Satisfaction and clinical utility of the adherence support programme is measured using patient note review and patient and carer interviews at baseline and after 12 weeks on service.
- Secondary Outcome Measures
Name Time Method Medication adherence is measured at baseline and study end point using an adherence assessment tool (MMAS-8) to establish the level of medication adherence. In addition, data on medication adherence will be collected from the Biodose dashboard between baseline and three months.